The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in the past decade. Reproducible manufacturing of high-quality, clinical-grade, genetically engineered HSCs is the foundation for broadening the application of this technology. Herein, the current state-of-the-art manufacturing platforms to genetically engineer HSCs as well as the challenges pertaining to production standardization and product characterization are addressed in the context of primary immunodeficiency diseases (PIDs) and other monogenic disorders.
Since the discovery of hematopoietic stem cells (HSCs) in the 1960s, HSC transplantation has become a curative clinical approach for an ever-increasing number of indications in oncology and regenerative medicine due to the unique self-renewal potential of HSCs. 1 Given the experience with HSC transplantation, the genetic modification of autologous HSCs is an attractive therapeutic option for patients with monogenic disorders who lack a suitable HSC donor. By now, nearly two decades of clinical experience with the use of genetically modified autologous HSCs have been accumulated in patients with primary immunodeficiency diseases (PIDs). Although this treatment modality has proven to be efficacious for the treatment of PIDs such as severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), X-linked severe combined immunodeficiency (X-SCID), and Wiskott-Aldrich syndrome (WAS), many challenges remain for the treatment of diseases such as chronic granulomatous disease (CGD) [2] [3] [4] or hemoglobinopathies. 5 Nonetheless, the recent approval of engineered HSCs for the treatment of patients with ADA-SCID provides an unprecedented proof of concept that paves the way for future applications. 6 The genetic engineering and manufacturing processes are critical for the broadening of HSC-based therapies. Here, we review the current status of HSC transduction in the context of the largely successful clinical applications for the treatment of PIDs (X-SCID, ADA-SCID, WAS, and CGD) as well as other monogenic disorders such as adrenoleukodystrophy (ALD) and metachromatic leukodystrophy (MLD).
Manufacturing of Genetically Engineered HSCs
For patients with suitable donors, allogeneic HSC transplantation (HSCT) is accepted as the overt first line of therapy with proven efficacy in patients with immunodeficiency diseases such as ADA-SCID, X-SCID, and WAS. For patients without matched donors, clinical studies have demonstrated long-lasting and curative effects of genetically engineered autologous HSCs with the bona fide elimination of the risk of graft-versus-host disease (GvHD). 2, 4, 7 The survival rate in patients with ADA-SCID has reached 100%, surpassing the efficacy of HSCT with fully matched donors. 8 The successful manufacturing of genetically engineered HSCs is the basis for this unparalleled positive outcome. Processes ranging from HSC collection, CD34
+ hematopoietic progenitor stem cells (HPSCs) selection, ex vivo activation/expansion, and genetic engineering of HSPCs must fulfill their own specific requirements to warrant a suitable clinical-grade product (Figure 1 ).
HPSC Collection
The primary sources for autologous hematopoietic progenitor and stem cells (HPSCs) are either bone marrow (BM) or mobilized peripheral blood (MPB). Several clinical trials have established that a minimum of 2 Â 10 6 CD34 + cells/kg body weight is needed for successful engraftment, and 5-10 Â 10 6 CD34 + cells/kg body weight is desirable for faster engraftment in the autologous setting.
9,10
In their quiescent state, HSPCs are tethered to osteoblasts, stromal cells, and the extracellular matrix in the BM stem cell niche. BM has been collected and infused into patients for more than 60 years.
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When BM is chosen as the collection source, a surgical procedure is required. Patients undergo general or regional anesthesia and BM is collected through a needle inserted into the rear of the hip, which contains a large concentration of blood stem cells. When mobilized peripheral blood is chosen as the HSC source, HSCs need to be released from their BM niche to allow them to migrate into the bloodstream. The US Food and Drug Administration (FDA) has approved three agents for the mobilization of HSPCs: two hematopoietic growth factors, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF); and a small bicyclam molecule, Plerixafor (also known as AMD3100). G-CSF is the first-line treatment for HPSC mobilization and has been shown to reduce neutropenia-related infection and enhance http://dx.doi.org/10.1016/j.omtm.2017.03.003. post-transplant myeloid recovery.
12 GM-CSF is less efficacious in mobilizing HSPCs 13 and considered a salvage mobilization regiment in patients who failed G-CSF mobilization. Plerixafor inhibits the CXCR4-SDF1 interaction within the BM microenvironment and induces rapid mobilization of stem cells.
14 It has recently been shown that a combination of Plerixafor and G-CSF results in enhanced mobilization of HSPCs with greater repopulating potential in donors with multiple myeloma, 15 non-Hodgkin lymphoma, 16 and thalassemia, 17 suggesting that distinct HPSC populations may be liberated from their specific niches by two different mechanisms. The COBE Spectra is the most commonly used platform for leukapheresis. The Spectra Optia system (Spectra's next generation), Haemonetics' MCS + , Fresenius Kabi's COM.TEC, and Fenwal's Amicus became more recently available for leukapheresis collection. The Spectra Optia and the Spectra systems have been shown to generate comparable HPSC products, yielding the least amount of red cell contamination, whereas the Amicus system removes fewer platelets from the donor. Gamma-Retroviral Vectors.
The Moloney murine leukemia (MLV)-based g retroviral vector (gRV) with intact long terminal repeats (LTRs) was among the first vectors employed for HSC gene therapy. More than 40 ADA-SCID patients have been treated with this vector, yielding 100% survival and 75% disease-free survival without detectable insertional mutagenesis.
37,38 However, despite marked clinical benefits in 20 X-SCID patients treated with CD34 + HSPCs transduced with MLV gRV expressing the common cytokine receptor g chain, 39 5 of them developed T cell acute lymphoblastic leukemia due to gRV insertion-induced transactivation of LMO2 or CCND2 proto-oncogenes. [40] [41] [42] Similarly, 7 of 10 patients treated with HSPCs transduced with MLV gRV encoding WAS protein developed leukemia associated with the dysregulation of LMO2 or with secondary myeloid malignancy as a result of insertional mutations in the MDS-Evi 1 locus. [43] [44] [45] The gRV SF71pg91 phox vector in 57 and MLD (n = 9) 58, 59 patients have undergone adverse events related to LV insertional mutagenesis postautologous HSC gene therapy except one patient with thalassemia. In this patient, a single myeloid progenitor clone emerged upon trans-activation at the HMGA2 locus and eventually regressed after 7 years upon presumed exhaustion of the mutated clone. Importantly, this clone never progressed to leukemia. 60 In-depth molecular analysis of the reconstituted hematopoiesis in patients with various diseases and treated with different types of vectors has allowed the characterization of vector-insertion distribution. 61 Unlike the early intact gRV LTRs, chimeric LV LTRs elicit much less frequent dominant clones and display different insertion site preferences. 63 Upon collection and selection, the large majority of CD34 + cells from BM and MPB are in G0/G1 phases of the cell cycle; in addition, the BM-derived CD34 + cells contain approximately 10% of cells in S and G2/M phases. 64 Stem cell factor (SCF) has been shown to effectively activate HSPCs for transduction when using a retroviral vector. 65 The most commonly used activation conditions combine SCF, Fms-like tyrosine kinase 3 ligand (Flt3-L), thrombopoietin (TPO), and interleukin 3 (IL-3) for both gRV-and LV-mediated gene transfer (Table 1) .
After pre-stimulation ranging from 14 to 40 hr, CD34 + cells are exposed to one or multiple rounds of transduction using either gRV or LV in presence of the same pre-stimulation cytokine cocktail. RetroNectin-coated tissue culture bags are frequently used to facilitate the transduction. The time in culture ranges from 2 to 5 days, resulting in transduction efficiency encompassing a wide range (Table 1) . In order to minimize HSC differentiation and to maintain their pluripotency, the time in culture is kept short. In addition, maintaining the cultures for less than 4 days following the transduction allows archiving the quality control (QC) samples for replication-competent lentivirus (RCL) while alleviating the need to perform this expensive test. 66 The transduced cell populations are subsequently harvested, washed, formulated, and released for patient infusion either fresh or upon cryopreservation.
For the trials listed in Table 1 , Cartier et al. 57 reported the use of cryopreserved cell products with hematopoietic recovery occurring at day 13 to 15 post-infusion, whereas other patients were treated with cells post-formulation without cryopreservation. For cryopreserved stem cell products, post-thaw viability constitutes one of the release tests. It has been recently reported that the viability of cryopreserved peripheral blood stem cells does not always correlate with the functional colony formation activity and engraftment outcome. 67 Cryopreservation has a direct impact on the engraftment potential of stem cells from BM, peripheral blood (PB), and cord blood sources. Fast freeze rate is deleterious to clonogenic recovery and could be a major factor for engraftment failure. [68] [69] [70] Thus, caution must be taken in designing rate-controlled freezer programs when using cryopreserved stem cell products.
HSC Gene Therapy Quality Control
Because the production processes are patient specific, moving forward this personalized cellular therapy toward a standard therapy poses great challenges.
The manufacturing procedure needs to be carried out by trained manufacturing personnel under good manufacturing practices (GMPs) following validated conditions. The quality of genetically engineered HSCs is subject to donor-to-donor variability and is also dependent on the manufacturing environment, the quality of ancillary raw materials/reagents, and a robust, controlled, and reproducible manufacturing process to ensure product consistency with minimal risk of contamination. We previously published how our group validated the collection, transduction, and formulation of CD34 + cells derived from thalassemic patients genetically modified with a LV encoding a normal b-globin gene, prior to initiating the first phase I clinical trial approved by the FDA in the United States. 71 Product quality is built within every manufacturing step and established through process qualification procedures and robust validation studies. More recently, we extensively reviewed the qualification of manufacturing processes and ancillary components for manufacturing chimeric antigen receptor T cells, which also applies to the clinical manufacturing of genetically engineered HSPCs. 72 Herein, we will therefore focus on the release testing of HPSC products. 
Review
The product testing and release criteria are devised to address the fundamental properties of the product including safety, purity, identity, and potency. Safety requires the lack of harmful contaminations, such as microbial agents, endotoxin, and mycoplasma; purity is reflected by the percentage of CD34 + cells and the transduction efficiency in the final product; identity of the product is commonly defined by the level of transgene incorporation in the genome; and potency of the transduced HSCs is often determined through soft agar colony formation assay and level of transgene expression in progenitors. Table 2 summarizes examples of release assays for RV or LV vector-transduced HSCs. The release of the cell products for infusion is handled through the issuance of a certificate of analysis, which summarizes the specifications and characteristics of the products and the release tests that have been performed.
Future Perspectives
Since the initiation of the first gene therapy trial in ADA-SCID patients in 1990s, 73, 74 we have embraced the approval of HSC gene therapy as the first line of therapy for this disease. 6 Cumulative evidence shows that HSC gene therapy is an effective treatment for various immunodeficiencies, inherited blood disorders, and monogenic metabolic diseases. More than 150 patients who did not have a matched donor have been treated with gRV or LV vector-transduced HSPCs worldwide, the majority of which have demonstrated some clinical benefit (Table 1) .
However, many challenges remain to be overcome. Standardization and automation of the manufacturing process await to be further developed. A very promising semi-automated system was recently reported to successfully transduce and manufacture non-human primate autologous gene-modified CD34 + cell products that were capable of stable, polyclonal multilineage reconstitution. 75 This process is likely to be adapted to the transduction of human HPSCs.
It is advisable to further develop cell manufacturing processes based on quality-by-design (QbD) principles. 76 In order for HSC-based therapies to realize their transformative potential, QbD principles should allow the linkage of measurable molecular and cellular characteristics of the cell population to final product quality. 77 A well-designed manufacturing platform should take into account the complexity of process scheduling, traceability, and time to release given the unique nature of this personalized medicine.
Vector insertional mutagenesis is still a major safety concern. The safety profiles for lentiviral vector-based trials are encouraging, 51, 55, 59 and follow-up of these patients is ongoing. The maturation of geneediting technologies, such as zinc finger endonuclease, 78 TALEN, 79 and CRISPR/Cas, 80 also offers new prospects and promises for in situ gene correction and may allow to take advantage of the endogenous regulatory machinery to drive the physiological level of gene expression. 81 The approval of HSC gene therapy for ADA-SCID is likely to widen the interest from industry and biotechnology companies, which will help develop automation platforms to enable commercialization. Certain existing platforms used in CAR-T cell manufacturing might also be suitable for genetically engineered-HSC production. 72 The field of HSC gene therapy is evolving at a fast pace. Successful clinical applications are poised to promote this exciting treatment modality to the forefront of standard of care in the near future. 13. Quittet, P., Ceballos, P., Lopez, E., Lu, Z.Y., Latry, P., Becht, C., Legouffe, E. 
